Proteome-based plasma markers of brain amyloid-β deposition in non-demented older individuals

Journal of Alzheimer's Disease

Volumn 22, Issue 4, 2010, Pages 1099-1109

  Thambisetty, Madhav ^a   Tripaldi, Romina ^b   Riddoch Contreras, Joanna ^b   Hye, Abdul ^b   An, Yang ^a   Campbell, James ^c   Sojkova, Jitka ^a   Kinsey, Anna ^b   Lynham, Steven ^b   Zhou, Yun ^d   Ferrucci, Luigi ^a   Wong, Dean F ^d   Lovestone, Simon ^b   Resnick, Susan M ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Proteome Sciences Plc   (United Kingdom)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; amyloid ; biomarker; brain; plasma; proteomics

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; COMPLEMENT COMPONENT C3; HAPTOGLOBIN; IMMUNOGLOBULIN HEAVY CHAIN; PITTSBURGH COMPOUND B; PLASMA PROTEIN; PLASMINOGEN; SERUM ALBUMIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; BRAIN REGION; BRAIN TISSUE; CLEARANCE; ENTORHINAL CORTEX; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HETEROZYGOTE; HIPPOCAMPUS; HOMOZYGOTE; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MALE; NEUROPATHOLOGY; NUCLEOTIDE SEQUENCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN LOCALIZATION; PROTEOMICS; RISK FACTOR; TANDEM MASS SPECTROMETRY; TEMPORAL LOBE; TISSUE DISTRIBUTION; TWO DIMENSIONAL GEL ELECTROPHORESIS;

EID: 78651372043     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-101350     Document Type: Article

References (51)

1. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356. (Pubitemid 34790756)
2. Rodrigue KM, Kennedy KM, Park DC (2009) Beta-amyloid deposition and the aging brain. Neuropsychol Rev 19, 436-450.
3. Pogacic V, Herrling P (2009) List of drugs in development for neurodegenerative diseases. Update June 2008. Neurodegener Dis 6, 37-86.
4. Resnick SM, Sojkova J, Zhou Y, An Y, Ye W, Holt DP, Dannals RF, Mathis CA, Klunk WE, Ferrucci L, Kraut MA, Wong DF. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology 74, 807-815
5. Storandt M, Mintun MA, Head D, Morris JC (2009) Cognitive decline and brain volume loss as signatures of cere-bralamyloid-beta peptide depositionidentified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol 66, 1476-1481.
6. Nordberg A (2007) Amyloid imaging in Alzheimer's disease. Curr Opin Neurol 20, 398-402. (Pubitemid 47051985)
7. Blennow K, Vanmechelen E, Hampel H (2001) CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol 24, 87-97. (Pubitemid 34066679)
8. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM (2003) Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289, 2094-2103. (Pubitemid 37430211)
9. Song F, Poljak A, Smythe GA, Sachdev P (2009) Plasma biomarkers for mild cognitive impairment and Alzheimer's disease. Brain Res Rev 61, 69-80.
10. Fehlbaum-Beurdeley P, Jarrige-Le Prado AC, Pallares D, Carriere J, Guihal C, Soucaille C,Rouet F, Drouin D, Sol O, Jordan H, Wu D, Lei L, Einstein R, Schweighoffer F, Bracco L (2010) Toward an Alzheimer's disease diagnosis via high-resolution blood gene expression. Alzheimers Dement 6, 25-38.
11. Ewers M, Mielke MM, Hampel H (2010) Blood-based biomarkers of microvascular pathology in Alzheimer's disease. Exp Gerontol 45, 75-79.
12. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L,Quinn JF, Rabinovi-ci GD, Robinson WH, Sabbagh MN,SoYT, Sparks DL, Taba-ton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T (2007) Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13, 1359-1362. (Pubitemid 350073592)
13. Schneider P, Hampel H, Buerger K (2009) Biological marker candidates of Alzheimer's disease in blood, plasma, and serum. CNS Neurosci Ther 15, 358-374.
14. Thambisetty M, Hye A, Foy C, Daly E, Glover A, Cooper A, Simmons A, Murphy D, Lovestone S (2008) Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease. J Neurol 255, 1712-1720.
15. Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y, Wahlund LO, Westman E, Kinsey A, Guntert A, Proitsi P, Powell J, Causevic M, Killick R, Lunnon K, Lyn-ham S, Broadstock M, Choudhry F, Howlett DR, Williams RJ, Sharp SI, Mitchelmore C, Tunnard C,Leung R, Foy C, O'Brien D, Breen G, Furney SJ, Ward M, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Hodges A, Murphy DG, Parkins S, Richardson JC, Resnick SM, Ferrucci L, Wong DF, Zhou Y, Muehlboeck S, Evans A, Francis PT, Spenger C, Lovestone S. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 67, 739-748.
16. Resnick SM, Goldszal AF, Davatzikos C, Golski S, Kraut MA, Metter EJ, Bryan RN, Zonderman AB (2000) One-year age changes in MRI brain volumes in older adults. Cereb Cortex 10, 464-472. (Pubitemid 30318453)
17. Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, Hooper C, Rijsdijk F, Tabrizi SJ, Banner S, Shaw CE, Foy C, Poppe M, Archer N, Hamilton G, Powell J, Brown RG, Sham P, Ward M, Lovestone S (2006) Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129, 3042-3050. (Pubitemid 44684524)
18. Hixson JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31, 545-548. (Pubitemid 20107994)
19. Geladi P, Kowalski BR (1986) Partial least-squares regression: a tutorial. Analytica Chimica Acta 185, 1-17.
20. Sojkova J, Beason-Held L, Zhou Y, An Y, Kraut MA, Ye W, Ferrucci L, Mathis CA, Klunk WE, Wong DF, Resnick SM (2008) Longitudinal cerebral blood flow and amyloid deposition: an emerging pattern? J Nucl Med 49, 1465-1471.
21. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, Holt DP, Meltzer CC, DeKosky ST, Mathis CA (2005) Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 25, 1528-1547. (Pubitemid 41541962)
22. Zhou Y, Resnick SM, Ye W, Fan H, Holt DP, Klunk WE, Mathis CA, Dannals R, WongDF (2007) Usinga reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease. Neuroimage 36, 298-312. (Pubitemid 46710457)
23. Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH (2003) An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage 19, 1233-1239. (Pubitemid 36918259)
24. Soares HD, Chen Y, Sabbagh M, Rohrer A, Schrijvers E, Breteler M (2009) Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels. Ann N Y Acad Sci 1180, 56-67.
25. Coon KD, Myers AJ, CraigDW, Webster JA, Pearson JV, Lince DH, Zismann VL, Beach TG, Leung D, Bryden L, Halperin RF, Marlowe L, Kaleem M, Walker DG, Ravid R, Heward CB, Rogers J, Papassotiropoulos A, Reiman EM, Hardy J, Stephan DA (2007) A high-density whole-genome association study reveals that APOEis the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry 68, 613-618. (Pubitemid 46663046)
26. Kim J, Basak JM, Holtzman DM (2009) The role of apolipoprotein E in Alzheimer's disease. Neuron 63, 287-303.
27. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, Dickinson KL, Maruff P, Darby D, Smith C, Woodward M, Merory J, Tochon-Danguy H, O'Keefe G, Klunk WE, Mathis CA, Price JC, Masters CL, Villemagne VL (2007) Imaging beta-amyloid burden in aging and dementia. Neurology 68, 1718-1725. (Pubitemid 46763260)
28. Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J (2001) Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci U S A 98, 3334-3339. (Pubitemid 32220846)
29. Small GW, Ercoli LM, Silverman DH, Huang SC, Komo S, Bookheimer SY, Lavretsky H, Miller K, Siddarth P, Rasgon NL, Mazziotta JC, Saxena S, Wu HM, Mega MS, Cummings JL, Saunders AM, Pericak-Vance MA, Roses AD, Barrio JR, Phelps ME (2000) Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 97, 6037-6042. (Pubitemid 30367519)
30. DuaraR,Loewenstein DA, Potter E, Appel J, Greig MT, Urs R, Shen Q, Raj A, Small B, Barker W, Schofield E, Wu Y, Potter H (2008) Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer disease. Neurology 71, 1986-1992.
31. Feng Z, Prentice R, Srivastava S (2004) Research issues and strategies for genomic and proteomic biomarker discovery and validation: a statistical perspective. Pharmacogenomics 5, 709-719. (Pubitemid 39236584)
32. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA (2010) APOE predicts amyloid-beta but not tau alzheimer's pathology in cognitively normal aging. Ann Neurol 67, 122-131.
33. Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB, Alexander GE, Klunk WE, Mathis CA, Price JC, Aizenstein HJ, DeKosky ST, Caselli RJ (2009) Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 106, 6820-6825.
34. Brooks JO, 3rd, Yesavage JA (1995) Identification of fast and slow decliners in Alzheimer disease: a different approach. Alzheimer Dis Assoc Disord 9 Suppl 1, S19-25.
35. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C (2009) Age, neuropathology, and dementia. N Engl J Med 360, 2302-2309.
36. Holtzman DM (2004) In vivo effects of ApoE and clusterin on amyloid-beta metabolism and neuropathology. J Mol Neurosci 23, 247-254.
37. Yerbury JJ, Wilson MR (2010) Extracellular chaperones modulate the effects of Alzheimer's patient cerebrospinal fluid on Abeta(1-42) toxicity and uptake. Cell Stress Chaperones 15, 115-121.
38. Yerbury JJ, Kumita JR, Meehan S, Dobson CM, Wilson MR (2009) alpha2-Macroglobulin and haptoglobin suppress amyloid formation by interacting with prefibrillar protein species. J Biol Chem 284, 4246-4254.
39. Jacobsen JS, Comery TA, Martone RL, Elokdah H, Crandall DL, Oganesian A, Aschmies S, Kirksey Y, Gonzales C, Xu J, ZhouH,Atchison K,Wagner E,Zaleska MM, Das I,Arias RL, Bard J, Riddell D, Gardell SJ, Abou-Gharbia M, Robichaud A, Magolda R, Vlasuk GP, Bjornsson T, Reinhart PH, Pangalos MN (2008) Enhanced clearanceofAbetain brainbysustaining the plasmin proteolysis cascade. Proc Natl Acad Sci U S A 105, 8754-8759. (Pubitemid 351987752)
40. Melchor JP, Strickland S (2005) Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost 93, 655-660. (Pubitemid 40485400)
41. van Vliet P, Westendorp RG, Eikelenboom P, Comijs HC, Frolich M, Bakker E, van der Flier W, van Exel E (2009) Parental history of Alzheimer disease associated with lower plasma apolipoprotein E levels. Neurology 73, 681-687.
42. Braak H, Braak E (1996) Evolution of the neuropathology of Alzheimer's disease. Acta Neurol Scand Suppl 165, 3-12. (Pubitemid 26143161)
43. Siest G, Bertrand P, Qin B, Herbeth B, Serot JM, Masana L, Ribalta J, Passmore AP, Evans A, Ferrari M, Franceschi M, Shepherd J, Cuchel M, Beisiegel U, Zuchowsky K, Rukavina AS, Sertic J, Stojanov M, Kostic V, Mitrevski A, Petrova V, Sass C, Merched A, Salonen JT, Tiret L, Visvikis S (2000) Apolipoprotein E polymorphism and serum concentration in Alzheimer's disease in nine European centres: the ApoEurope study. ApoEurope group. Clin Chem Lab Med 38, 721-730.
44. Evans AE, Zhang W, Moreel JF, Bard JM, Ricard S, Poirier O, Tiret L, Fruchart JC, Cambien F (1993) Polymorphisms of the apolipoprotein B and E genes and their relationship to plasma lipid variables in healthy Chinese men. Hum Genet 92, 191-197. (Pubitemid 23272288)
45. Moreno JA, Perez-Jimenez F, Moreno-Luna R, Perez-Martinez P, Fuentes-Jimenez F, Marin C, Portugal H, Lairon D, Lopez-Miranda J (2009) The effect of apoE genotype and sex on ApoE plasma concentration is determined by dietary fat in healthy subjects. Br J Nutr 101, 1745-1752.
46. Neale MC, de Knijff P, Havekes LM, Boomsma DI (2000) ApoE polymorphism accounts for only part of the genetic variation in quantitative ApoE levels. Genet Epidemiol 18, 331-340. (Pubitemid 30252592)
47. DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'Dell MA, Taylor JW, Harmony JA, Aronow BJ, Bales KR, Paul SM, Holtzman DM (2004) ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron 41, 193-202. (Pubitemid 38125181)
48. Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL (1984) Alzheimer's disease: cell-specific pathology isolates the hip-pocampal formation. Science 225, 1168-1170. (Pubitemid 14029099)
49. Frisoni GB, Lorenzi M, Caroli A, Kemppainen N, Nagren K, Rinne JO (2009) In vivo mapping of amyloid toxicity in Alzheimer disease. Neurology 72, 1504-1511.
50. Sperling RA, Laviolette PS, O'Keefe K, O'Brien J, Rentz DM, Pihlajamaki M, Marshall G, Hyman BT, Selkoe DJ, Hedden T, Buckner RL, Becker JA, Johnson KA (2009) Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 63, 178-188.
51. Citron M Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 9, 387-398.